Assembly Biosciences (ASMB)
(Delayed Data from NSDQ)
$15.04 USD
-0.09 (-0.59%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $15.00 -0.04 (-0.27%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
ASMB 15.04 -0.09(-0.59%)
Will ASMB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ASMB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ASMB
Are Medical Stocks Lagging Entera Bio (ENTX) This Year?
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
ASMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
TEVA Shares Rise on Broad Support for Opioids Settlement
After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB)
Assembly Biosciences (ASMB) Upgraded to Strong Buy: Here's Why
Other News for ASMB
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
H.C. Wainwright Sticks to Its Hold Rating for Assembly Biosciences (ASMB)
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
Assembly Biosciences doses first participant in Phase 1b trial of ABI-4334
Assembly Biosciences closes $12.6M in equity financings